The pathological results showed that 93.8% (76/81) of cases were invasive ductal carcinoma, 17.3% (14/81) were poorly differentiated (histological grade III) breast cancer, 30.0% (17/81) were triple-negative breast cancer, and 2.47% (2/81) Her2-overexpressing breast cancer (Table 2). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.